Form 4: Coya Therapeutics CFO Awarded Stock Options

Coya Therapeutics' Chief Financial Officer, David S. Snyder, was granted stock options for 140,562 shares on January 9, 2025.

Summary

• David S. Snyder, the Chief Financial Officer of Coya Therapeutics, Inc., was granted stock options to purchase 140,562 shares of common stock.
• The options have an exercise price of $6.07 per share.
• The options vest in monthly installments over 36 months, starting on February 9, 2025, contingent upon continuous service.
• The options expire on January 9, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The granting of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The value of the stock options is dependent on the future performance of Coya Therapeutics' stock price.
• If the stock price does not increase above the exercise price, the options may not be valuable to the CFO.

Future Outlook

The stock options will vest over the next 36 months, subject to the CFO's continued employment.

Industry Context

Granting stock options to executives is a common practice in the biotechnology industry to incentivize performance and align management's interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 36 months is typical for such grants, aligning with long-term performance goals.
• The exercise price of $6.07 is a key factor in determining the value of the options, and will be compared to the market price of the stock over time.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to increase the company's value.
• The CFO is incentivized to remain with the company for the vesting period.

Key Dates

Keywords

stock options, Coya Therapeutics, David S. Snyder, executive compensation, equity, vesting